The results showed that elevated PTX3 expression was associated with reduced survival rates in patients with G3, G4, IDH wild-type, 1p/19q alterations, as well as in both female and male patients diagnosed with astrocytoma or glioblastoma. This evidence concerns the gene PTX3 and astrocytoma (excluding glioblastoma).